BACKGROUND: Targeted gene NGS testing is available through many academic institutions and commercial entities and is increasingly incorporated in practice guidelines for glioblastoma (GBM). This single-center retrospective study aimed to evaluate the clinical utility of incorporating NGS results in the management of GBM patients at a clinical trials-focused academic center. METHODS: We identified 1011 consecutive adult patients with pathologically confirmed GBM (IDHwt or IDHmut) who had somatic tumor sequencing (Oncopanel, ~500 cancer gene panel) at DFCI from 2013-2019. Clinical records of all IDHwt GBM patients were reviewed to capture clinical trial enrollment and off-label targeted therapy use based on NGS results. RESULTS: Of the 557 IDHwt GBM patients with sequencing, 182 entered clinical trials at diagnosis (32.7%) and 213 (38.2%) entered after recurrence. Sequencing results for 130 patients (23.3%) were utilized for clinical trial enrollment for either targeted therapy indications (6.9 % upfront and 27.7% at recurrent clinical trials and 3.1% for off-label targeted therapy) or exploratory studies (55.4% upfront and 6.9% recurrent clinical trials). Median overall survival was 20.1 months with no survival difference seen between patients enrolled in clinical trials compared to those who were not, in a posthoc analysis. CONCLUSIONS: While NGS testing has become essential for improved molecular diagnostics, our study illustrates that targeted gene panels remain underutilized for selecting therapy in GBM-IDHwt. Targeted therapy and clinical trial design remain to be improved to help leverage the potential of NGS in clinical care.
BACKGROUND: Targeted gene NGS testing is available through many academic institutions and commercial entities and is increasingly incorporated in practice guidelines for glioblastoma (GBM). This single-center retrospective study aimed to evaluate the clinical utility of incorporating NGS results in the management of GBM patients at a clinical trials-focused academic center. METHODS: We identified 1011 consecutive adult patients with pathologically confirmed GBM (IDHwt or IDHmut) who had somatic tumor sequencing (Oncopanel, ~500 cancer gene panel) at DFCI from 2013-2019. Clinical records of all IDHwt GBM patients were reviewed to capture clinical trial enrollment and off-label targeted therapy use based on NGS results. RESULTS: Of the 557 IDHwt GBM patients with sequencing, 182 entered clinical trials at diagnosis (32.7%) and 213 (38.2%) entered after recurrence. Sequencing results for 130 patients (23.3%) were utilized for clinical trial enrollment for either targeted therapy indications (6.9 % upfront and 27.7% at recurrent clinical trials and 3.1% for off-label targeted therapy) or exploratory studies (55.4% upfront and 6.9% recurrent clinical trials). Median overall survival was 20.1 months with no survival difference seen between patients enrolled in clinical trials compared to those who were not, in a posthoc analysis. CONCLUSIONS: While NGS testing has become essential for improved molecular diagnostics, our study illustrates that targeted gene panels remain underutilized for selecting therapy in GBM-IDHwt. Targeted therapy and clinical trial design remain to be improved to help leverage the potential of NGS in clinical care.
Authors: Patrick Y Wen; Michael Weller; Eudocia Quant Lee; Brian M Alexander; Jill S Barnholtz-Sloan; Floris P Barthel; Tracy T Batchelor; Ranjit S Bindra; Susan M Chang; E Antonio Chiocca; Timothy F Cloughesy; John F DeGroot; Evanthia Galanis; Mark R Gilbert; Monika E Hegi; Craig Horbinski; Raymond Y Huang; Andrew B Lassman; Emilie Le Rhun; Michael Lim; Minesh P Mehta; Ingo K Mellinghoff; Giuseppe Minniti; David Nathanson; Michael Platten; Matthias Preusser; Patrick Roth; Marc Sanson; David Schiff; Susan C Short; Martin J B Taphoorn; Joerg-Christian Tonn; Jonathan Tsang; Roel G W Verhaak; Andreas von Deimling; Wolfgang Wick; Gelareh Zadeh; David A Reardon; Kenneth D Aldape; Martin J van den Bent Journal: Neuro Oncol Date: 2020-08-17 Impact factor: 12.300
Authors: Tal Shahar; Erez Nossek; David M Steinberg; Uri Rozovski; Deborah T Blumenthal; Felix Bokstein; Razi Sitt; Sigal Freedman; Benjamin W Corn; Andrew A Kanner; Zvi Ram Journal: J Clin Neurosci Date: 2012-09-16 Impact factor: 1.961
Authors: Craig Horbinski; Keith L Ligon; Priscilla Brastianos; Jason T Huse; Monica Venere; Susan Chang; Jan Buckner; Timothy Cloughesy; Robert B Jenkins; Caterina Giannini; Roger Stupp; L Burt Nabors; Patrick Y Wen; Kenneth J Aldape; Rimas V Lukas; Evanthia Galanis; Charles G Eberhart; Daniel J Brat; Jann N Sarkaria Journal: Neuro Oncol Date: 2019-12-17 Impact factor: 12.300
Authors: Felix Sahm; Daniel Schrimpf; David T W Jones; Jochen Meyer; Annekathrin Kratz; David Reuss; David Capper; Christian Koelsche; Andrey Korshunov; Benedikt Wiestler; Ivo Buchhalter; Till Milde; Florian Selt; Dominik Sturm; Marcel Kool; Manuela Hummel; Melanie Bewerunge-Hudler; Christian Mawrin; Ulrich Schüller; Christine Jungk; Antje Wick; Olaf Witt; Michael Platten; Christel Herold-Mende; Andreas Unterberg; Stefan M Pfister; Wolfgang Wick; Andreas von Deimling Journal: Acta Neuropathol Date: 2015-12-15 Impact factor: 17.088
Authors: Kathryn M Field; Katharine J Drummond; Merve Yilmaz; Mark Tacey; Daniel Compston; Peter Gibbs; Mark A Rosenthal Journal: J Clin Neurosci Date: 2013-04-29 Impact factor: 1.961
Authors: Wolfgang Wick; Michael Platten; Christoph Meisner; Jörg Felsberg; Ghazaleh Tabatabai; Matthias Simon; Guido Nikkhah; Kirsten Papsdorf; Joachim P Steinbach; Michael Sabel; Stephanie E Combs; Jan Vesper; Christian Braun; Jürgen Meixensberger; Ralf Ketter; Regine Mayer-Steinacker; Guido Reifenberger; Michael Weller Journal: Lancet Oncol Date: 2012-05-10 Impact factor: 41.316
Authors: David W Ellison; Kenneth D Aldape; David Capper; Maryam Fouladi; Mark R Gilbert; Richard J Gilbertson; Cynthia Hawkins; Thomas E Merchant; Kristian Pajtler; Sriram Venneti; David N Louis Journal: Brain Pathol Date: 2020-06-23 Impact factor: 7.611
Authors: Mehdi Touat; Yvonne Y Li; Adam N Boynton; Liam F Spurr; J Bryan Iorgulescu; Craig L Bohrson; Isidro Cortes-Ciriano; Cristina Birzu; Jack E Geduldig; Kristine Pelton; Mary Jane Lim-Fat; Sangita Pal; Ruben Ferrer-Luna; Shakti H Ramkissoon; Frank Dubois; Charlotte Bellamy; Naomi Currimjee; Juliana Bonardi; Kenin Qian; Patricia Ho; Seth Malinowski; Leon Taquet; Robert E Jones; Aniket Shetty; Kin-Hoe Chow; Radwa Sharaf; Dean Pavlick; Lee A Albacker; Nadia Younan; Capucine Baldini; Maïté Verreault; Marine Giry; Erell Guillerm; Samy Ammari; Frédéric Beuvon; Karima Mokhtari; Agusti Alentorn; Caroline Dehais; Caroline Houillier; Florence Laigle-Donadey; Dimitri Psimaras; Eudocia Q Lee; Lakshmi Nayak; J Ricardo McFaline-Figueroa; Alexandre Carpentier; Philippe Cornu; Laurent Capelle; Bertrand Mathon; Jill S Barnholtz-Sloan; Arnab Chakravarti; Wenya Linda Bi; E Antonio Chiocca; Katie Pricola Fehnel; Sanda Alexandrescu; Susan N Chi; Daphne Haas-Kogan; Tracy T Batchelor; Garrett M Frampton; Brian M Alexander; Raymond Y Huang; Azra H Ligon; Florence Coulet; Jean-Yves Delattre; Khê Hoang-Xuan; David M Meredith; Sandro Santagata; Alex Duval; Marc Sanson; Andrew D Cherniack; Patrick Y Wen; David A Reardon; Aurélien Marabelle; Peter J Park; Ahmed Idbaih; Rameen Beroukhim; Pratiti Bandopadhayay; Franck Bielle; Keith L Ligon Journal: Nature Date: 2020-04-15 Impact factor: 49.962
Authors: James Stewart; Arjun Sahgal; Aimee K M Chan; Hany Soliman; Chia-Lin Tseng; Jay Detsky; Sten Myrehaug; Eshetu G Atenafu; Ali Helmi; James Perry; Julia Keith; Mary Jane Lim-Fat; David G Munoz; Gelareh Zadeh; David B Shultz; Sunit Das; Catherine Coolens; Paula Alcaide-Leon; Pejman Jabehdar Maralani Journal: Technol Cancer Res Treat Date: 2022 Jan-Dec